Clinical Trials
2 trialsNCT04984369 2023-08-21
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
Shanghai Henlius Biotech
Phase 2 Unknown
NCT05127759 2023-08-08
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
Shanghai Henlius Biotech
Phase 2 Unknown